Abstract:Gliomas, particularly glioblastoma (GBM), represent the most prevalent and aggressive tumors of the central nervous system (CNS). Despite recent treatment advancements, patient survival rates remain low. The diagnosis of GBM traditionally relies on neuroimaging methods such as magnetic resonance imaging (MRI) or computed tomography (CT) scans and postoperative confirmation via histopathological and molecular analysis. Imaging techniques struggle to differentiate between tumor progression and treatment-related changes, leading to potential misinterpretation and treatment delays. Similarly, tissue biopsies, while informative, are invasive and not suitable for monitoring ongoing treatments. These challenges have led to the emergence of liquid biopsy, particularly through blood samples, as a promising alternative for GBM diagnosis and monitoring. Presently, blood and cerebrospinal fluid (CSF) sampling offers a minimally invasive means of obtaining tumor-related information to guide therapy. The idea that blood or any biofluid tests can be used to screen many cancer types has huge potential. Tumors release various components into the bloodstream or other biofluids, including cell-free nucleic acids such as microRNAs (miRNAs), circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), proteins, extracellular vesicles (EVs) or exosomes, metabolites, and other factors. These factors have been shown to cross the blood-brain barrier (BBB), presenting an opportunity for the minimally invasive monitoring of GBM as well as for the real-time assessment of distinct genetic, epigenetic, transcriptomic, proteomic, and metabolomic changes associated with brain tumors. Despite their potential, the clinical utility of liquid biopsy-based circulating biomarkers is somewhat constrained by limitations such as the absence of standardized methodologies for blood or CSF collection, analyte extraction, analysis methods, and small cohort sizes. Additionally, tissue biopsies offer more precise insights into tumor morphology and the microenvironment. Therefore, the objective of a liquid biopsy should be to complement and enhance the diagnostic accuracy and monitoring of GBM patients by providing additional information alongside traditional tissue biopsies. Moreover, utilizing a combination of diverse biomarker types may enhance clinical effectiveness compared to solely relying on one biomarker category, potentially improving diagnostic sensitivity and specificity and addressing some of the existing limitations associated with liquid biomarkers for GBM. This review presents an overview of the latest research on circulating biomarkers found in GBM blood or CSF samples, discusses their potential as diagnostic, predictive, and prognostic indicators, and discusses associated challenges and future perspectives.

Molecular Biomarkers and Recent Liquid Biopsy Testing Progress: A Review of the Application of Biosensors for the Diagnosis of Gliomas

Progress in the Application of Molecular Biomarkers in Gliomas

Liquid biopsy: early and accurate diagnosis of brain tumor

The Progress in Molecular Biomarkers of Gliomas

A Review of Clinical Use of Surface-Enhanced Raman Scattering-Based Biosensing for Glioma.

Circulating Liquid Biopsy Biomarkers in Glioblastoma: Advances and Challenges

Electrochemical biosensors for early diagnosis of glioblastoma

Long Non-Coding RNAs As Potential Biomarkers and Therapeutic Targets for Gliomas.

Current Progress of Diagnostic and Prognostic Markers in Gliomas

Preoperative Diagnosis and Molecular Characterization of Gliomas With Liquid Biopsy and Radiogenomics

Novel Molecular Markers in Glioblastoma-Benefits of Liquid Biopsy

Cerebrospinal Fluid Biomarkers for Brain Tumor Detection: Clinical Roles and Current Progress.

Liquid Biopsy Strategies to Distinguish Progression from Pseudoprogression and Radiation Necrosis in Glioblastomas

Liquid biopsy and tumor DNA/RNA detection in the cerebrospinal fluid of patients diagnosed with central nervous system glioma - A review article

Evolution of Molecular Biomarkers and Precision Molecular Therapeutic Strategies in Glioblastoma

Current research status of Raman spectroscopy in glioma detection

Glioma nanomedicine: Design, fabrication and theranostic application

Circulating biomarkers literature in glioma patient populations

Liquid Biomarkers for Improved Diagnosis and Classification of CNS Tumors

Advances in early detection methods for solid tumors

Use of microRNAs as Diagnostic, Prognostic, and Therapeutic Tools for Glioblastoma